Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioElectronics Vice President of Sales Discusses Opioids and the Alternative Drug Free ActiPatch® Pain Therapy

BIEL

PHOENIX, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Uptick Newswire “Stock Day” podcast keeps investors up to date on the latest penny stock news by bringing transparency in the micro-cap side of the market. Connect with “Stock Day” and to over 600+ CEO interviews on the OTC, Pink Sheets and micro-cap news from around the world by following Stock Day’s YouTube, Google Play, and iTunes. Everett Jolly, CEO and host of “Stock Day” welcomes Keith Nalepka, Vice President of Sales and Marketing for BioElectronics Corporation (OTC Pink:BIEL) (the “Company”). 

Mr. Jolly was excited to point out that the stock price of BioElectronics Corporation is trading around .0009 cents, up almost 40% from the past time the Company made an appearance on “Stock Day”. “What’s going on?” Mr. Jolly asks. 

BioElectronics’ Vice President of Sales and Marketing explains that ActiPatch® the Company’s drug free medical device alternative to opioids has been approved by the respected United Kingdom’s National Health Service for reimbursement and that the Company and Care Pharmacies have launched its “Pharmacists Pain Management Consultations” in the US to help mitigate the drug crisis.

In its studies of UK patients, ActiPatch decreased medication use by 36% and professional office visits 58%.  These studies show good evidence for reducing the need for opioid medications as well as the special needs costs of chronic pain suffers. Nalepka is hopeful that this clinical support will encourage UK, US, and other physicians to recommend the ActiPatch® as well as help springboard sales of the FDA cleared nonprescription device.

“​ActiPatch®​is doing what it has always done providing safe and superior pain relief! My past success in pain products and retail leads me to believe that to get products into retail is a challenge for small companies but ActiPatch is a strong contender.” Anticipating a perfect storm, he states that “2018 is going to be a transformational year for this Company.” 

Listen to the full plan of execution here: https://upticknewswire.com/featured-interview-vp-of-sales-keith-nalepka-of-bioelectronics-corp-otcpink-biel .To listen to the interview in its entirety please click here.

About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona with its new host Kathryn Donnelly.

https://www.youtube.com/watch?v=kU5SVLp4org

Follow us and keep an eye on Uptick’s YouTube, Twitter, and Facebook​for additional radio and video shows produced by Uptick! https://www.youtube.com/watch?v=kU5SVLp4org

Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit BioElectonic’s message board on: https://investorshangout.com/BioElectronics-Corporation-BIEL-59005/

About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® device for chronic and post-operative wound care; and Allay® Menstrual Pain Therapy. For more information, please visit
www.bielcorp.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release.

Contact:
Uptick Newswire LLC
Everett Jolly, CEO/Founder
602-441-3474
10000 N. 31st Avenue C307 Phoenix, AZ 85051 info@upticknewswire.com
www.upticknewswire.com
Source: Uptick Newswire



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today